Today it was reported that the President & CEO of Enanta Pharmaceuticals (ENTA – Research Report), Jay Luly, exercised options to buy 7,052 ENTA shares at $14.18 a share, for a total transaction value of $100K.
This recent transaction increases Jay Luly’s holding in the company by 1.12% to a total of $37.07 million. In addition to Jay Luly, one other ENTA executive reported Buy trades in the last month.
The company has a one-year high of $106.80 and a one-year low of $57.15. ENTA’s market cap is $1.14B and the company has a P/E ratio of 18.85. Currently, Enanta Pharmaceuticals has an average volume of 219.76K.
The insider sentiment on Enanta Pharmaceuticals has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Jay Luly’s trades have generated a 12.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak.